(PharmaNewsWire.Com, January 26, 2018 ) The Global Biosimilar Market accounted to USD 3.5 billion in 2016 growing at a CAGR of 27.0% during the forecast period of 2017 to 2024. The upcoming market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.
Market Definition: Global Biosimilar Market
A biosimilar (called as follow-on biologic and subsequent entry biologic) is a biologic medical product that ispractically an identical copy of an original product that is man-made.Biosimilars are made only when the patent for the original product gets expired.Guidelines for biosimilars play a major role in retaining the viability and stability between original and biosimilars products. Numerous regulatory authorities which includeEMA and FDA actively regulate the biosimilars commercialization and development.
Demand of polyurethane in the building and construction industry
Increasing demand for rigid foam mainly for insulation purposes
Market Restraint:
Volatility in raw material prices
Market Segmentation: Global Biosimilar Market
The Biosimilar market is segmented on the basis of type into catalyst, surfactants, fillers and others.
On the basis of application, the market is segmented into flexible foam, rigid foam, adhesive & sealant, coating, elastomer, binders and other.
On the basis of end-user, the market is segmented into automotive, building & construction, and bedding & furniture and other.
On the basis of geography, the Biosimilar market report covers data points for 28 countries across multiple geographies such as North America, South America, Europe, Asia-Pacific and Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil among Major market Drivers and Restraints:
Increasing Incidence Of Chronic Diseases
Costly Patented Drugs
Expanding Geriatric Population
Technological and Procedural Restrictions
Nonexistence Of Supervisory Rules
Customers Brand Inclinations
Market Segmentation: Global Biosimilar Market
By product the global biosimilar market is segmented into recombinant non-glycosylated proteins, recombinant peptides, and recombinant glycosylated proteins.
Recombinant non-glycosylated proteins are further segmented into recombinant human growth hormone (RHGH),insulin, granulocyte colony-stimulating factor (Filgrastim), and interferons.
Recombinant Glycosylated Proteins are again bifurcated into monoclonal antibodies (MABS), erythropoietin (EPO), and follitropin.
Recombinant Peptidesare again divided into glucagon and calcitonin.
On the basis oftypes global biosimilar market is segmented intohuman growth hormone, erythropoietin, monoclonal antibodies, insulin, interferon, granulocyte-colony stimulating factor, and peptide.
On the basis ofthe manufacturingglobal biosimilar market is segmented intocontract manufacturing organizations and in-house manufacturing.
On the basis ofthe application global biosimilar market is segmented intooncology, chronic and autoimmune diseases, blood disorders, growth hormone deficiency, infectious diseases and others.
On the basis of end-user the global biosimilar market is segmented into retail pharmacies, and hospitals.
On the basis of geography, global biosimilar market report covers data points for 28 countries across multiple geographies such as North America & South America, Europe, Asia-Pacific, and Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil among others. In 2017, North America is expected to dominate the market.
The global biosimilar market is highly fragmented and is based on new product launches and clinical results of products. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of biosimilar market for global, Europe, North America, Asia Pacific and South America.
Major Market Competitors: Global Biosimilar Market
Some of the major players operating in global biosimilar market are3SBio Inc., Allergan, Amgen Inc., AstraZeneca, Baxter, Bharat Serums, Bio Sidus, Biogen, BioXpress TherapeuticsSA., Boehringer Ingelheim GmbH, Cipla Inc., Emcure Pharmaceuticals Ltd., GeneScience Pharmaceuticals Co., Ltd., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, Samsung BioLogics, Sanofi, and Zydus Cadila among others
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
